All In MedTech

Device Trial Radar · NCT06459778

Piezo-ICSI to Improve the Developmental Potential of Fertilized Oocytes in Aged Infertility Women With Assisted Reproductive Technology

A Single-center Randomized Controlled Trial on Piezo-ICSI Improving Oocyte Fertilization and Embryo Development in Elderly Infertile Patients

Last checked: Nov 19, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

147

Planned (sponsor's estimate)

Start

Nov 20, 2023

Primary completion

May 2026

Study completion May 2026

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 14, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 35 years, up to 42 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test Piezo-ICSI on improving oocyte fertilization and embryo development in elderly infertile patients undergoing intracytoplasmic sperm injection (ICSI). The main question it aims to answer is whether Piezo-ICSI could improve oocyte fertilization and embryo development. Participants requested ICSI are asked to randomly culture equal numbers of oocyte and embryo with or without Piezo-ICSI. At the time of injection, two or more mature oocytes were split into two groups (i) conventional ICSI and (ii) Piezo-ICSI (50:50 split).

Conditions

  • Infertility, Female
  • Intracytoplasmic Sperm Injections

Interventions

  • Piezo-ICSIDevice

    Participants had their oocytes cohort divided, where half were injected using conventional ICSI and the other half were injected using Piezo-ICSI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. fertilization rate post intracytoplasmic sperm injectionTime frame: 16-18 hours post intracytoplasmic sperm injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.